Loading…
Abeona Therapeutics Inc. is projected to rise to $7.91 by 2027, a +23% move from its current price of $6.42. ABEO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $6.26 | $6.42 | $6.59 | +0.04% |
| Aug 4 | $6.19 | $6.42 | $6.67 | +0.08% |
| Aug 5 | $6.14 | $6.43 | $6.73 | +0.12% |
| Aug 6 | $6.10 | $6.43 | $6.78 | +0.15% |
| Aug 7 | $6.06 | $6.43 | $6.82 | +0.19% |
| Aug 8 | $6.03 | $6.43 | $6.86 | +0.23% |
| Aug 9 | $6.00 | $6.44 | $6.90 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.00 | $6.44 | $6.90 | +0.27% |
| Week 2 | $5.85 | $6.45 | $7.12 | +0.54% |
| Week 3 | $5.74 | $6.47 | $7.30 | +0.82% |
| Week 4 | $5.65 | $6.49 | $7.46 | +1.09% |
| Week 5 | $5.57 | $6.51 | $7.60 | +1.36% |
| Week 6 | $5.50 | $6.53 | $7.74 | +1.64% |
| Week 7 | $5.44 | $6.54 | $7.87 | +1.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company that develops gene and cell therapies for life-threatening diseases in the United States. It focuses on ZEVASKYN, an autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa, and ABO-503 to treat X-linked retinoschisis; ABO-504 for Stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.
It is also developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc.
in June 2015. Abeona was founded in 1974 and is headquartered in Cleveland, Ohio.
Abeona Therapeutics Inc. (ABEO) is active in the healthcare sector with a current price of $6.47 and a market cap of $368.76M. It holds a rank of 3094 among tracked assets. These figures place ABEO within a broad market context as a commercial-stage biopharmaceutical company developing gene and cell therapies.
For the near term, the forecast shows a neutral stance in 2026 with an average price of $6.47, a low of $4.23, and a high of $8.81; ROI 0 and sentiment NEUTRAL.
Looking further out, the forecast points to a bullish trajectory: 2027 avg $7.94, 2028 $9.47, 2029 $11.13, and 2030 $15.01 with an ROI of 132. The path continues through 2040 at $42.29 (ROI 553.6) and 2050 at $106.45 (ROI 1545.3), all with bullish sentiment.
A major floor 34.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.4% below — buyers have tended to step in here.
The nearest ceiling, 13.6% above — a clean break opens room to run.
A major ceiling 27.0% above — clearing it would confirm fresh momentum.
Key ABEO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABEO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.25 | Buy | $6.34 | Buy |
| MA 10 | $6.31 | Buy | $6.38 | Buy |
| MA 20 | $6.61 | Sell | $6.39 | Buy |
| MA 50 | $6.04 | Buy | $6.12 | Buy |
| MA 100 | $5.59 | Buy | $5.82 | Buy |
| MA 200 | $5.32 | Buy | $5.62 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.11 | Neutral |
| Stoch RSI (14) | 28.13 | Neutral |
| CCI (20) | -38.26 | Neutral |
| Williams %R (14) | -68.50 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -11.93 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 31.50 | Neutral |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 47.38 | Neutral |
| Momentum (10) | -0.58 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 6.32 | Buy |
| ADX (14) | 17.55 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term technical picture is bullish, with RSI(14) at 50. The 50-day simple moving average sits at $6.02 and the 200-day simple moving average at $5.31, indicating a positive trend relative to longer-term price movement.
In terms of support and resistance, the chart shows a support level at $5.56 and a resistance level at $7.29. Over the last 30 days, the price ranged between $5.41 and $7.74, highlighting a narrow window for near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.23 | $6.42 | $8.74 | 0% | Neutral | |
| $6.33 | $7.91 | $10.43 | +23% | Bullish | |
| $7.33 | $9.41 | $12.88 | +47% | Bullish | |
| $8.46 | $11.11 | $15.64 | +73% | Bullish | |
| $11.12 | $14.90 | $21.49 | +132% | Bullish | |
| $12.89 | $17.57 | $25.87 | +174% | Bullish | |
| $13.59 | $18.85 | $28.27 | +194% | Bullish | |
| $15.08 | $21.23 | $32.39 | +231% | Bullish | |
| $15.97 | $22.82 | $35.36 | +255% | Bullish | |
| $17.34 | $25.13 | $39.50 | +291% | Bullish | |
| $27.35 | $42.28 | $70.59 | +559% | Bullish | |
| $61.70 | $106.40 | $193.99 | +15.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.23 | $6.42 | $7.84 | +0.00% |
| September 2026 | $5.50 | $6.49 | $7.89 | +1.16% |
| October 2026 | $5.59 | $6.65 | $8.16 | +2.41% |
| November 2026 | $5.82 | $6.96 | $8.61 | +4.69% |
| December 2026 | $5.83 | $7.01 | $8.74 | +0.65% |
Click any year to see its month-by-month ABEO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ABEO could reach as high as $8.74, with a base case around $6.42 and support toward $4.23 — roughly 0% from $6.42. Price action looks broadly range-bound.
Expect ABEO to range from $6.33 to $10.43 through 2027. The $7.91 average target implies a +23% move from current prices. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ABEO price prediction for 2028 points to an average of $9.41 (low $7.33, high $12.88) — a potential gain of +47% on today's $6.42. Momentum favours further upside here.
In 2029, ABEO is projected to trade between $8.46 and $15.64, averaging $11.11 — a potential gain of +73% from today's $6.42. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Abeona Therapeutics Inc.'s 2030 outlook centres on $14.90, within a $11.12 to $21.49 range. That is up +34% on the projected 2029 average. That marks a +132% change versus current levels. Momentum favours further upside here.
By 2031, ABEO could reach as high as $25.87, with a base case around $17.57 and support toward $12.89 — roughly +174% from $6.42. Buyers look set to stay in control over this stretch.
Expect ABEO to range from $13.59 to $28.27 through 2032. The $18.85 average target implies a +194% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The ABEO price prediction for 2033 points to an average of $21.23 (low $15.08, high $32.39) — a potential gain of +231% on today's $6.42. Buyers look set to stay in control over this stretch.
In 2034, ABEO is projected to trade between $15.97 and $35.36, averaging $22.82 — a potential gain of +255% from today's $6.42. That is up +7% on the projected 2033 average. Momentum favours further upside here.
Abeona Therapeutics Inc.'s 2035 outlook centres on $25.13, within a $17.34 to $39.50 range. That is up +10% on the projected 2034 average. That marks a +291% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ABEO could reach as high as $70.59, with a base case around $42.28 and support toward $27.35 — roughly +559% from $6.42. Momentum favours further upside here.
Expect ABEO to range from $61.70 to $193.99 through 2050. The $106.40 average target implies a +15.6x move from current prices. That is up +152% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABEO today (≈ 155.76324 ABEO) could be worth
$16,573.81
+$15,573.81 (+1557%) by 2050 · US Dollar
Based on the average projected ABEO price of $106.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABEOwould be worth at today's price.
$1,000 invested in ABEO on Jul 31, 2025 (≈ 156.985874 ABEO) would be worth
$1,007.85
+$7.85 (+0.8%) today · 1.01× · US Dollar
Based on a ABEO entry price of $6.37 vs. today's $6.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.05 | $1,061.16 | +6.1% |
| 1 month ago | $6.05 | $1,061.16 | +6.1% |
| 3 months ago | $5.43 | $1,182.32 | +18.2% |
| 6 months ago | $5.17 | $1,241.78 | +24.2% |
| 1 year ago | $6.37 | $1,007.85 | +0.8% |
| All time (5.0y) ago | $30.75 | $208.78 | -79.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABEO forecast.
Our base-case forecast reaches $13.00 around 2030.
Implied market cap at $13.00: $740.94M
The multi-year forecast depicts a strong upward trajectory. The average price is projected to rise to $15.01 in 2030, supported by an ROI of 132 and bullish sentiment. By 2040, the average climbs to $42.29 with an ROI of 553.6, and by 2050 the average reaches $106.45 with an ROI of 1545.3, continuing the bullish trend.
These figures illustrate a long-run upside, but they are estimates and not guarantees. Uncertainty and potential downside risk remain, and outcomes can vary with market conditions and company performance. The outlook remains bullish on longer horizons.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $15.01 with a minimum of $11.15 and a maximum of $21.77, and an ROI of 132, with bullish sentiment.
The forecast presents a bullish long-term path, with rising averages and positive ROIs from 2027 onward, including 2030 ($15.01 avg, ROI 132) and beyond, though these are estimates and not guarantees.
Yes. The 2050 forecast lists an average price of $106.45 and a maximum of $196.17, with an ROI of 1545.3 and bullish sentiment.
Current price is $6.47 and market cap is $368.76M, with a rank of 3094.
For 2026, the min is $4.23, the avg is $6.47, the max is $8.81, ROI is 0, and sentiment is NEUTRAL.
Abeona Therapeutics Inc. Community Discussion
0Share your Abeona Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.